NDAORALTABLET
Approved
Jan 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
76
Data completeness
6/8 — Strong
CADUET (amlodipine and atorvastatin) by Pfizer is drugs, a dihydropyridine calcium channel blocker (amlodipine) and an hmg-coa reductase inhibitor (atorvastatin). Approved for hypertension, hyperlipidemia. First approved in 2004.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CADUET is a fixed-dose combination tablet containing amlodipine (a calcium channel blocker) and atorvastatin (an HMG-CoA reductase inhibitor) approved for hypertension and hyperlipidemia. It combines peripheral vasodilation and blood pressure reduction with cholesterol synthesis inhibition and LDL particle reduction. This dual-mechanism oral tablet simplifies treatment for patients requiring both cardiovascular and lipid management.
$0.222MPart D
LOE ApproachingDeclining
Product is in late-stage decline with minimal Part D utilization (180 claims in 2023), signaling reduced team investment and fewer growth opportunities.
Mechanism of Action
drugs, a dihydropyridine calcium channel blocker (amlodipine) and an HMG-CoA reductase inhibitor (atorvastatin). The amlodipine component of amlodipine and atorvastatin tablets inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The atorvastatin…
Worked on CADUET at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.